ALTIMMUNE, INC. Available-for-sale Securities, Short-term Investments, Amortized Cost (Deprecated 2018-01-31)
ALTIMMUNE, INC. (ALT) had Available-for-sale Securities, Short-term Investments, Amortized Cost (Deprecated 2018-01-31) of $66.81 million as of 2016-12-31, per its 10-K filed 2017-03-14.
Discontinued › Notes › Investments
us-gaap:AvailableForSaleSecuritiesShortTermInvestmentsAmortizedCost · last filed 2017-03-14
- 2016-12-31: Available-for-sale Securities, Short-term Investments, Amortized Cost (Deprecated 2018-01-31) $66.81M.
- 2016-09-30: Available-for-sale Securities, Short-term Investments, Amortized Cost (Deprecated 2018-01-31) $66.83M.
| Period end | Available-for-sale Securities, Short-term Investments, Amortized Cost (Deprecated 2018-01-31) |
|---|---|
| 2016-12-31 | $66.81M 10-K · filed 2017-03-14 |
| 2016-09-30 | $66.83M 10-Q · filed 2016-11-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B |